Padualaan 8 (postvak 133)
94 articles with Merus
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zenocutuzumab (Zeno) for the treatment of patients with pancreatic cancer. Zeno is a first in class bispecific antibody that potently binds to
Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 3:30 p.m. ET.
Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates
– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecific antibodies provides important insights and avenues to maximize T‑cell engager biology – UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a
Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and TriclonicsTM), today announced financial results for the first quarter that ended March 31, 2020, and provided a business update.
Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update
Merus N.V. announced financial results for the fourth quarter and full year ended December 31, 2019, and provided a business update.
Merus N.V., a clinical-stage company developing innovative, full-length bispecific antibodies, announced financial results for the third quarter ended September 30, 2019 and provided a business update.
Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of $14.50 per share, before underwriting discounts and commissions.
Merus N.V., a clinical-stage bispecific antibody company developing Biclonics®, announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being offered by Merus N.V.
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.
Merus Announces First Patient Dosed in a Phase II Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
Combination trial to evaluate MCLA-128 in HER2-positive and hormone receptor-positive/HER2-low metastatic breast cancer patients.
Under the deal, Merus has agreed to lead research and discovery activities while Simcere has agreed to be responsible for the Investigational New Drug (IND) enabling studies, clinical development, regulatory filings and commercialization of these product candidates in China.
The company announced that it has submitted an IND application to the U.S. FDA for MCLA-117.
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Regeneron filed the complaint against Merus alleging that it infringed one or more claims in the '018 patent in 2014.
Merus ended the third quarter of 2017 with cash and cash equivalents of €202.4 million compared to €56.9 million at December 31, 2016.